Judah Frommer
Stock Analyst at Morgan Stanley
(4.00)
# 558
Out of 5,182 analysts
188
Total ratings
64.58%
Success rate
6.31%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics | Initiates: Overweight | $14 | $6.02 | +132.56% | 1 | Apr 16, 2026 | |
| IMMX Immix Biopharma | Initiates: Overweight | $20 | $9.53 | +109.86% | 1 | Mar 25, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $19 → $18 | $14.27 | +26.14% | 3 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Equal-Weight | $19 → $21 | $18.59 | +12.96% | 3 | Mar 17, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $18 → $17 | $8.62 | +97.22% | 4 | Mar 6, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $163.06 | +23.27% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $11.32 | +147.35% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $26.64 | +27.63% | 1 | Feb 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $111.90 | +29.58% | 4 | Jan 9, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $25.00 | +44.00% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $26 | $40.95 | -36.51% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $33.66 | +27.75% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $28.55 | -22.94% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $9.45 | -36.51% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $115.07 | -7.88% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $22.48 | +55.73% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $1.86 | +61.29% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $0.93 | +4,201.54% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.52 | +415.87% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $33.71 | -31.77% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $69.22 | -27.77% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $20.98 | +572.07% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.34 | +107.37% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $30.45 | -27.75% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $6.29 | +11.29% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.72 | +3.63% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $131.45 | -65.01% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.91 | +266.49% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $17.90 | +207.26% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $135.98 | -66.17% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $88.67 | -44.74% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $998.01 | -62.93% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $91.00 | -65.93% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $75.36 | +0.85% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $117.35 | +55.09% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $98.00 | +9.18% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $92.05 | +3.20% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $16.57 | +8.63% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $234.25 | -50.48% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $92.89 | -59.09% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $71.62 | -69.28% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $65.90 | -46.89% | 9 | Apr 29, 2020 |
Kalaris Therapeutics
Apr 16, 2026
Initiates: Overweight
Price Target: $14
Current: $6.02
Upside: +132.56%
Immix Biopharma
Mar 25, 2026
Initiates: Overweight
Price Target: $20
Current: $9.53
Upside: +109.86%
Trevi Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $19 → $18
Current: $14.27
Upside: +26.14%
Zenas BioPharma
Mar 17, 2026
Maintains: Equal-Weight
Price Target: $19 → $21
Current: $18.59
Upside: +12.96%
REGENXBIO
Mar 6, 2026
Maintains: Overweight
Price Target: $18 → $17
Current: $8.62
Upside: +97.22%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $163.06
Upside: +23.27%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $11.32
Upside: +147.35%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $26.64
Upside: +27.63%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $111.90
Upside: +29.58%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $25.00
Upside: +44.00%
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $40.95
Upside: -36.51%
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $33.66
Upside: +27.75%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $28.55
Upside: -22.94%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $9.45
Upside: -36.51%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $115.07
Upside: -7.88%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $22.48
Upside: +55.73%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.86
Upside: +61.29%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $0.93
Upside: +4,201.54%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.52
Upside: +415.87%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $33.71
Upside: -31.77%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $69.22
Upside: -27.77%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $20.98
Upside: +572.07%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.34
Upside: +107.37%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $30.45
Upside: -27.75%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $6.29
Upside: +11.29%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.72
Upside: +3.63%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $131.45
Upside: -65.01%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.91
Upside: +266.49%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $17.90
Upside: +207.26%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $135.98
Upside: -66.17%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $88.67
Upside: -44.74%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $998.01
Upside: -62.93%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $91.00
Upside: -65.93%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $75.36
Upside: +0.85%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $117.35
Upside: +55.09%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $98.00
Upside: +9.18%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $92.05
Upside: +3.20%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $16.57
Upside: +8.63%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $234.25
Upside: -50.48%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $92.89
Upside: -59.09%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $71.62
Upside: -69.28%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $65.90
Upside: -46.89%